Download PDF
Thromb Haemost 1999; 82(S 01): 130-135
DOI: 10.1055/s-0037-1615571
Commentaries
Schattauer GmbH

Anticoagulation after Artificial Valve Replacement with or without Atrial Fibrillation: How Much Is Really Needed?

Freek W. A. Verheugt
1   From the Department of Cardiology, Heartcenter, University Hospital Nijmegen, Nijmegen, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
14 December 2017 (online)

    Permissions and Reprints

Summary

Insertion of a mechanical artificial heart valve is an absolute indication for the use of lifelong oral anticoagulation, irrespective the presence or absence of atrial fibrillation. Depending on the type and position of the artificial valve the optimal International Normalized Ratio (INR) for these patients is between 2.5 and 4.5, although more prospective studies on the optimal range of oral anticoagulation are necessary. Addition of low dose antiplatelet therapy may further decrease the rate of thromboembolism, but also here more studies are needed. Patients with a bioprosthesis need only oral anticoagulation for the first three months following surgery in the absence of an indication for anticoagulation for other conditions.

Atrial fibrillation is often seen in patients with artificial heart valves. Stroke prevention can be instituted by the mandatory oral anticoagulant therapy. The presence of atrial fibrillation and the use of oral anticoagulation prior to heart valve surgery support the indication for the insertion of a mechanical artificial heart valve. However, relative contraindications to oral anticoagulation and the presence of sinus rhythm may favor the use of a bioprosthesis.

Key words

Anticoagulation - heart valve prosthesis - heart valve bioprosthesis - atrial fibrillation - thromboembolism
 

  • References

  • 1 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke. The Framingham study. Arch Intern Med 1987; 147: 1561-4.
    PubMedGoogle Scholar
  • 2 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death myocardial infarction and stroke by prolonged antipla-telet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
    CrossrefPubMedGoogle Scholar
  • 3 Saour JN, Sieck JO, Mamo LAR, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-32.
    CrossrefPubMedGoogle Scholar
  • 4 Acar J, Iung B, Boissel JP. et al. Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996; 94: 2107-12.
    CrossrefPubMedGoogle Scholar
  • 5 Cannegieter SC, Rosendaal FR, Wintzen AR, Van der Meer FJ, Vanden-broucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
    CrossrefPubMedGoogle Scholar
  • 6 Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635-41.
    CrossrefPubMedGoogle Scholar
  • 7 Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AGG. Antithrombotic therapy in patients with mechanical and prosthetic heart valves. Chest 1995; 108: 371-9.
    CrossrefPubMedGoogle Scholar
  • 8 Altman R, Boullon F, Rouvier J, Raca R, de la, Fuente L, Favaloro R. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thor Cardiovasc Surg 1976; 72: 127-9.
    PubMedGoogle Scholar
  • 9 Dale J, Myhre E, Rootwelt K. Effects of dipyridamole and acetylsalicylic acid on platelet functions in patients with aortic ball-valve prostheses. Am Heart J 1975; 89: 613-8.
    CrossrefPubMedGoogle Scholar
  • 10 Chesebro JH, Fuster V, Elveback LR. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 5 1 1537-41.
    PubMedGoogle Scholar
  • 11 Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basille F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524-9.
    CrossrefPubMedGoogle Scholar
  • 12 Verheugt FWA. Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease. J Cardiovasc Risk 1996; 3: 229-32.
    PubMedGoogle Scholar
  • 13 Stroke Prevention in Atrial Fibrillation Study Group Investigators. The Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: 527-39.
    CrossrefPubMedGoogle Scholar
  • 14 Connolly SJ, Laupaucis A, Gent M, Roberts RS, Cairns JA, Joyner C. and CAFA Study Co-investigators Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-55.
    CrossrefPubMedGoogle Scholar
  • 15 Ezekowitz ME, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian AM, Radford MJ, Rickles FR, Shabetai R, Deykin D. and the VA SPINAF Investigators Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-12.
    CrossrefPubMedGoogle Scholar
  • 16 Peterson P, Boysen G, Godfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet 1989; i: 175-9.
    PubMedGoogle Scholar
  • 17 Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
    CrossrefPubMedGoogle Scholar
  • 18 Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91.
    PubMedGoogle Scholar
  • 19 Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-11.
    CrossrefPubMedGoogle Scholar